Biogen on SPi NewsFollow our SPi News RSS Feed for biogen

Featured biogen News

[30 Oct 2019] Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

[29 Oct 2019] Galimedix Therapeutics, Inc.’s GAL-101 Gains from Target Validation by Positive Phase 3 Results of Biogen’s Aducanumab

[01 Oct 2019] Biogen Announces Leadership Update

[17 Sep 2019] Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index

[07 Jun 2019] Nightstar Therapeutics PLC Completion of Acquisition by Biogen

[07 Jun 2019] Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million

[05 Jun 2019] Nightstar Therapeutics plc Court Approval Received in Connection With Acquisition by Biogen

[29 May 2019] Nightstar Therapeutics plc Update to Timetable Relating to the Acquisition by Biogen

[20 May 2019] Biogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation

[07 May 2019] Data at AAN Demonstrate Biogen’s Leadership and Commitment to Innovation in MS

[29 Apr 2019] Biogen Announces Three New Nominees for Election to Board of Directors

[21 Mar 2019] Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease

[04 Mar 2019] Nightstar Therapeutics plc reaches agreement to be acquired by Biogen

[02 Mar 2019] Biogen Responds to CADTH’s updated recommendation regarding coverage for SPINRAZA

[20 Dec 2018] Biogen Applauds Quebec Decision to Cover SPINRAZA™ (nusinersen) for a broad population of SMA Patients

[17 Oct 2018] IMRALDI™, Biogen’s Adalimumab Biosimilar Referencing Humira®, Is Launched in the European Union

[11 Oct 2018] Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis

[20 Jul 2018] Biogen to Host Investor Webcast to Discuss Alzheimer’s Disease Portfolio on July 25, 2018

[28 Jun 2018] Biogen Exercises Option to Increase Ownership in Samsung Bioepis

[28 Jun 2018] Biogen Exercises Option to Increase Ownership in Samsung Bioepis

[19 Jun 2018] Biogen to Host Investor Webcast on Its Efforts Targeting Stroke on June 28, 2018

[18 Jun 2018] Biogen Foundation Selects Grantees to Receive $10 Million Investment for STEM Education

[13 Jun 2018] Biogen Enhances Commitment to SMA Research with Data Presented at Annual SMA Conference

[13 Jun 2018] Biogen Enhances Commitment to SMA Research with Data Presented at Annual SMA Conference

[07 Jun 2018] Biogen Enters Exclusive Option Agreement to Acquire TMS' Phase 2 Asset for Acute Stroke

[07 Jun 2018] Biogen Enters Exclusive Option Agreement to Acquire TMS’ Phase 2 Asset for Acute Stroke

[31 May 2018] Biogen Appoints Daniel Karp as EVP, Corporate Development

[31 May 2018] Biogen Appoints Daniel Karp as EVP, Corporate Development

[15 Mar 2018] Biogen to Present at the 2018 Advances in Alzheimer’s and Parkinson’s Therapies (AAT-AD/PD) Focus Meeting

[25 Jan 2018] Karyopharm Announces Agreement for Biogen to Acquire KPT-350 for the Treatment of Neurological and Neurodegenerative Conditions

[28 Aug 2017] Biogen Reports New Data from Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab

[31 May 2017] Biogen Announces Webcast of Virtual Annual Meeting of Stockholders

[09 Feb 2017] Forward Pharma Received US$ 1.25bn pursuant to Settlement and License Agreement with Biogen

[17 Jan 2017] Forward Pharma Agrees to Enter Into Settlement and License Agreement with Biogen

[17 Jan 2017] Siemens Healthineers and Biogen Announce Agreement to Jointly Develop New MRI Tools for Multiple Sclerosis

[24 Oct 2016] Labaton Sucharow LLP Files Class Action Lawsuit on Behalf of Biogen Inc. Investors

[28 Sep 2016] Anavex Compound to be Tested in Biogen Neurological Protection Model

[22 Jul 2016] Medidata Cloud Technology Selected to Support Biogen Clinical Trials

[19 May 2016] Biogen Announces Webcast of Virtual Annual Meeting of Stockholders

[06 Jan 2016] Rodin Announces New Equity Financing and R&D Collaboration with Biogen

[05 Jan 2016] Jacobs Wins Contract with Biogen

[24 Nov 2015] Sobi and Biogen's Elocta® (rFVIIIFc) approved in Europe for the treatment of haemophilia A

[08 Oct 2015] BIOGEN, INC. SHAREHOLDER ALERT: Kessler Topaz Meltzer & Check, LLP Announces Shareholder Class Action Against Biogen Inc. -- BIIB

[25 Sep 2015] Biogen and Sobi receive positive opinion from CHMP for Elocta(TM) (rFVIIIFc) for the treatment of Haemophilia A

[02 Jul 2015] AGTC to Host Conference Call and Webcast to Discuss Biogen Collaboration

[23 Jun 2015] Biogen Achieves Carbon Neutrality

[31 Jul 2014] The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene

[28 Jul 2014] The Zacks Analyst Blog Highlights: Verizon Communications, Apple, Biogen, Boeing and Caterpillar

[07 Jul 2014] Biotech Equities under the Scanner -- Research on Alexion Pharma, InterMune, Cytokinetics, and Biogen Idec

[12 Jun 2014] The Zacks Analyst Blog Highlights:Clovis, Biogen, Halozyme, Ariad and Chart Industries


Still looking?

Type in your search term below and click Enter

World News from SPi

Sector Publishing Intelligence [SPi'] publishes financial news from around the world FAST. For breaking news announcements from companies, blogs and commentators, SPi provides up to the minute, integrated news on all aspects of financial markets and financial services.

SPi's extensive database of corporate information shows company details alongside breaking corporate news from the world’s largest news providers.

Publish Your Stories with SPI

Please click here to find out how to submit press releases and articles for publication.

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2020. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us